NDA 20663, held by Mylan Bertek. Butenafine Hydrochloride.
As of Nov 13, 2026, NDA 20663 (Mentax), held by Mylan Bertek, was first approved by FDA on Dec 31, 1996, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 1996 | Original applicationTYPE 6 · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mentax1% · cream; topical | Butenafine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
